Description

RxSight® is an ophthalmic medical technology corporation headquartered in Aliso Viejo, California that has commercialized the world’s first and only adjustable intraocular lens (IOL) that is customized after cataract surgery. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye.

OVERVIEW:

Engineer I, IOL Development plays a vital role in supporting the development of next-generation processes and products. This is an on-site role that requires working directly with the product and utilizing a wide range of metrology equipment.

Working closely with a team of engineers, you will conduct experiments, run pilot builds, and be relied on to provide critical feedback with minimal supervision. You will be comfortable generating, analyzing, and presenting data (including managing datasets for parallel projects).

You will co-develop experiments to challenge the production of critical steps of our technology, including but not limited to the LAL. This role demands technical expertise, professionalism, and the ability to collaborate effectively across multiple departments including but not limited to Engineering, Manufacturing and Chemistry.

Requirements

ESSENTIAL DUTIES AND RESPONSIBILITIES:

Responsible for improving the performance and quality of RxSight products and for supporting the engineering and implementation of advanced technologies, focused primarily on the Light Adjustable Lens (LAL) system and related accessories
Support development of Next Generation manufacturing processes including mechanical and electromechanical systems
Design, execute, and troubleshoot complex experiments with minimal supervision, ensuring thorough data collection and detailed documentation.
Work closely with engineering to execute design experiments (DOEs) for troubleshooting or development. Ensure data is organized, presentable and traceable.
Partners with R&D technicians to ensure detailed experiments are executed according to plan, taking ownership of experimental flow and data collection
Provide live updates on project progress, communicating any delays, challenges, or mistakes transparently to prevent disruptions.
Comfortable using a wide range of equipment including but not limited to optical metrology (OCT, SmartScope, Comparator, Confocal Microscope)
Design and implement (including driving release through QMS system when necessary) fixtures to support LAL sample built, inspections, and manufacturing processes
Perform independent engineering studies to support feasibility of next-generation products and processes
Write engineering reports, work instructions, and drive release through QMS system when necessary
Review and understand mechanical and assembly drawings – comfortable providing feedback
Continuously challenge the process and actively seek improvements

REQUIRED KNOWLEDGE, SKILLS, AND ABILITIES:

Technical Curiosity: Understands the impact and logic behind new projects or processes and takes pride in the criticality of the work
Accountability and Transparency: Demonstrates responsibility and openness in communicating progress and challenges to the team and supervisors. Ensures integrity of data and study metrics that the group is responsible for.
Consistency and reliability: Systematic focus on tasks and delivers data and/or results within the allotted timeframe
Collaborative Spirit: Ability to work effectively with management and cross-functional teams to achieve project goals - willingness to help others, including management and peers.
Product Development Expertise: Knowledge of prototyping, manufacturing, and testing processes including Design of Experiments (DOE) familiarization.
Validation and Regulatory Compliance: Expertise in IQ, OQ, PQ processes and awareness of relevant industry regulations.
Data Analysis: Ability to analyze complex data sets and provide clear insights for decision-making.
Problem-Solving: Strong troubleshooting skills for technical challenges and equipment-related issues.
Strong Organizational skills: Ability to balance and prioritize multiple studies, and manufacturing builds.
Adaptability: Ability to manage shifting priorities and operate efficiently in a fast-paced environment.
Attention to Detail: Ensure precision in documentation, experimentation, and process execution.

SUPERVISORY RESPONSIBILITIES:

None

EDUCATION, EXPERIENCE, and TRAINING:

Basic understanding of DFM and manufacturing principles (part machining a plus)
Understanding of GMP and GDP
Understanding of Design Control process
Minimum of 1 year in a manufacturing environment (medical device preferred)
Experience with ERP systems (knowledge of QAD a plus)
Strong communication skills – written and verbal
Experience with general laboratory and metrology equipment
Training to be completed per the training plan for this position as maintained in the document control system
The training requirements on TRN-10007 Insider Trading Policy, TRN-10008 Global Anti-Bribery and Anti-Corruption Policy and TRN-10009 Code of Business Conducts and Ethics must be diligently completed within 30 days from the hiring date and on an annual basis

CERTIFICATES, LICENSES, REGISTRATIONS:

Bachelor’s degree in engineering or physics

COMPUTER SKILLS:

SolidWorks (preferred, not required)
Enterprise PDM
Microsoft Office Suite (Word Processing, Spreadsheets, Presentations)
Design Software
Project Management System

Notice to Staffing Agencies and Search Firms:

RxSight does not accept unsolicited resumes or candidate submissions from staffing agencies or search firms for any employment opportunities. All agency engagements must be authorized in writing for a specific position by RxSight’s Talent Acquisition department. Any resumes or candidate information submitted without such specific engagement will be considered unsolicited and the property of RxSight. No fees will be paid in the event a candidate is hired under these circumstances.

About the company

RxSight develops medical devices for vision correction in cataract surgery. Its flagship product is the Light Adjustable Lens (LAL), an intraocular lens that can be adjusted after implantation using a Light Delivery Device (LDD) to achieve the best possible vision. How it works: after the LAL is implanted, doctors use controlled light exposure via the LDD to fine-tune the lens power post-operatively, allowing precise refractive outcomes before finalizing vision. How RxSight differs from competitors: instead of relying on fixed lenses, it offers an adjustable lens system that enables post-operative customization, paired with a dedicated delivery device and support for ophthalmologists and clinics to optimize patient results. Its goal is to improve quality of life for patients with cataracts and corneal astigmatism by delivering superior, individualized visual outcomes and expanding access to precise vision correction in the cataract market.

Company Size

201-500

Company Stage

IPO

Headquarters

Aliso Viejo, California

Founded

1997

Get referred to RxSight

See people who can refer or advise you

Simplify's Take

What believers are saying

Alcon paid $60 million upfront in July 2026 and can add $140 million.
RxSight ended Q2 2026 with about $209 million cash and investments.
Australia's 2026 launch broadened access, and more than 325,000 LALs are implanted globally.

What critics are saying

Q2 2026 revenue fell 20%; management blamed competitive launches and weaker procedure volumes.
The May 2026 securities case denial sends RxSight into costly discovery through 2027.
If repeat utilization stalls, RxSight's standalone business loses scale and survives on Alcon royalties.

What makes RxSight unique

RxSight sells the only commercially available post-implant adjustable intraocular lens, the LAL.
Surgeons fine-tune refraction after cataract surgery using the Light Delivery Device.
Alcon's July 2026 collaboration validates RxSight's platform as category-defining ophthalmic technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Stock Options
Company Equity

Company News

MarketScreener

Oct 19th, 2026

RxSight appoints eye care industry leaders to drive commercial transformation.

RxSight appoints eye care industry leaders to drive commercial transformation. Published on 10/19/2026 at 09:03 am EDT GlobeNewswire ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) - RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy. The appointments strengthen RxSight's commercial leadership team and support the company's efforts to enhance commercial execution and accelerate adoption of RxSight's Light Adjustable Lens(TM)(LAL(TM) technology. "Over the past several months, we have prioritized investment to strengthen our commercial organization, and the appointments of Taryn and Frank are another important step in that process," said Aziz Mottiwala, President and Chief Executive Officer of RxSight. "Their extensive experience in eye care and track record of driving the adoption of innovative technologies will be instrumental as we advance the next phase of our commercial strategy, with a greater emphasis on customer engagement and utilization." Taryn Conway, Chief Commercial Officer Conway brings more than 20 years of experience building commercial organizations across eye care, pharmaceuticals and medical aesthetics. Most recently, she served as Vice President of Medical and Scientific Affairs at Bausch + Lomb, overseeing medical strategy across its pharmaceutical and consumer businesses. Prior to that, she was General Manager of Aesthetics at Revance Therapeutics, where she built and scaled a commercial organization from the ground up and led the commercialization of two major product lines. Earlier in her career, she held senior leadership positions at Allergan, developing deep expertise in ophthalmology, physician engagement and market development. Frank Shields, Executive Vice President of Sales and Commercial Strategy Shields brings over 30 years of ophthalmology leadership experience, with a distinguished record of guiding commercial organizations, launching transformative technologies, and building lasting relationships with physicians, customers, and industry partners. Prior to joining RxSight, he served as a Head of U.S. Surgical Glaucoma at Bausch + Lomb following its acquisition of Elios Vision, where he was President. Earlier, he held sales leadership roles at Ivantis, Revision Optics and Bausch + Lomb, with experience across cataract, refractive and glaucoma technologies. These appointments are part of RxSight's broader commercial transformation, which includes expanding and realigning its field organization to enable deeper customer engagement and increased support, so even more patients can benefit from RxSight's LAL technology. The changes are designed to help practices integrate this differentiated technology into their workflows and address barriers to broader utilization. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The Light Adjustable Lens(TM) system, comprised of the RxSight Light Adjustable Lens(TM) products (LAL(TM) and LAL+(TM), RxSight Light Delivery Device(TM)(LDD(TM), and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements in this press release that are not purely historical are forward-looking statements, including, without limitation, statements regarding the RxSight's business initiatives and prospects. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks described in the RxSight's prior press releases and the company's filings with the Securities and Exchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of the company's Quarterly Report on Form 10-Q for the period ended June 30, 2026, filed with the SEC on August 5, 2026, and any subsequent filings with the SEC. These statements are only predictions based on our current expectations and projections about future events. Actual events or results may differ materially. RxSight undertakes no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. Light Adjustable Lens(TM), LAL(TM), LAL+(TM), Light Delivery Device(TM) and LDD(TM) are trademarks of RxSight, Inc. Investor Relations Contact: Oliver Moravcevic VP, Investor Relations [email protected] (C) GlobeNewswire - 2026

MarketBeat

Sep 2nd, 2026

RxSight (NASDAQ:RXST) COO Ilya Goldshleger sells 2,041 shares of stock.

RxSight (NASDAQ:RXST) COO Ilya Goldshleger sells 2,041 shares of stock. September 2, 2026 Key points. * RxSight COO Ilya Goldshleger sold 2,041 shares at an average price of $6.96, generating $14,205.36. The sale covered tax withholding obligations tied to vested equity awards, reducing his holdings by 2.44% to 81,509 shares. * RxSight shares rose 0.6% to $7.03, with the company valued at approximately $292.4 million. Its stock has traded between $4.48 and $13.22 over the past year. * The company recently exceeded quarterly expectations, reporting a loss of $0.29 per share versus the projected $0.33 loss and revenue of $33.74 million. Analyst sentiment remains cautious, with an average "Reduce" rating and an average price target of $8.37. * MarketBeat previews the top five stocks to own by October 1st. RxSight, Inc. (NASDAQ:RXST - Get Free Report) COO Ilya Goldshleger sold 2,041 shares of the business's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total transaction of $14,205.36. Following the completion of the sale, the chief operating officer owned 81,509 shares in the company, valued at $567,302.64. This represents a 2.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. RxSight trading up 0.6%. NASDAQ:RXST traded up $0.04 during midday trading on Wednesday, hitting $7.03. 778,865 shares of the company traded hands, compared to its average volume of 898,096. The firm has a market capitalization of $292.40 million, a P/E ratio of -6.22 and a beta of 1.16. RxSight, Inc. has a 12-month low of $4.48 and a 12-month high of $13.22. The firm's fifty day moving average is $5.95 and its 200-day moving average is $6.35. RxSight (NASDAQ:RXST - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.35%. The company had revenue of $33.74 million for the quarter, compared to the consensus estimate of $32.55 million. On average, research analysts expect that RxSight, Inc. will post -1.01 EPS for the current fiscal year. Wall Street analyst weigh in. A number of equities analysts have commented on RXST shares. Needham & Company LLC reissued a "buy" rating and set a $11.00 target price on shares of RxSight in a report on Tuesday, July 7th. Bank of America dropped their price objective on shares of RxSight from $8.00 to $6.50 and set an "underperform" rating for the company in a report on Tuesday, July 7th. Stifel Nicolaus decreased their price objective on shares of RxSight from $8.00 to $7.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Jefferies Financial Group set a $6.50 target price on shares of RxSight in a research report on Tuesday, July 7th. Finally, UBS Group boosted their price objective on RxSight from $5.50 to $6.30 and gave the company a "neutral" rating in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Reduce" and an average target price of $8.37. Institutional trading of RxSight. Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in shares of RxSight in the 2nd quarter worth $28,000. Summit Securities Group LLC purchased a new position in shares of RxSight in the first quarter valued at $30,000. Larson Financial Group LLC grew its stake in shares of RxSight by 110.5% during the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company's stock valued at $36,000 after acquiring an additional 2,089 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in RxSight by 440.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company's stock worth $39,000 after purchasing an additional 3,063 shares during the last quarter. Finally, CWM LLC raised its holdings in RxSight by 211.1% in the fourth quarter. CWM LLC now owns 3,826 shares of the company's stock valued at $40,000 after acquiring an additional 2,596 shares in the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors. About RxSight. RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company's flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non-invasive post-operative adjustments. Using ultraviolet light, surgeons can fine-tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction. Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider RxSight, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list. While RxSight currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Yahoo Finance

Aug 13th, 2026

Alcon and RxSight partner to develop adjustable intraocular lenses for cataract surgery

Alcon and RxSight announced a strategic partnership on 6 July to co-develop post-operatively adjustable intraocular lenses. The collaboration combines RxSight's light-adjustable technology, which allows surgeons to fine-tune patients' vision using UV light after surgery, with Alcon's global commercial reach and surgical equipment portfolio. Alcon reported strong Q1 2026 results with net sales of $2.7 billion, up 10% year-over-year. Core diluted earnings per share rose 16% to $0.85, whilst core operating margin reached 21.2%. The company generated $279 million in free cash flow and authorised a new $1.5 billion share repurchase programme. RxSight's Q1 2026 revenue fell 18.5% to $30.9 million due to lower Light Delivery Device sales. Despite this, gross profit margin improved to 76.1%. The company's net loss widened to $15.9 million, though it maintains $217.9 million in cash reserves.

MarketBeat

Aug 10th, 2026

Stifel Nicolaus lowers RxSight (NASDAQ:RXST) price target to $7.00.

Stifel Nicolaus lowers RxSight (NASDAQ:RXST) price target to $7.00. August 10, 2026 Key points. * Stifel Nicolaus lowered RxSight's price target from $8.00 to $7.00 while maintaining a "hold" rating, implying 11.82% potential upside from the prior close. * Analyst sentiment remains cautious: RxSight has two Buy, seven Hold, and three Sell ratings, resulting in a MarketBeat consensus rating of "Reduce" and an average price target of $8.37. * RxSight reported better-than-expected quarterly results, with an adjusted loss of $0.29 per share versus the $0.33 consensus estimate and revenue of $33.74 million versus $32.55 million expected. * Five stocks to consider instead of RxSight. RxSight (NASDAQ:RXST - Get Free Report) had its price target cut by Stifel Nicolaus from $8.00 to $7.00 in a report released on Monday,Benzinga reports. The brokerage presently has a "hold" rating on the stock. Stifel Nicolaus' price target suggests a potential upside of 11.82% from the stock's previous close. RXST has been the topic of several other reports. UBS Group lifted their target price on RxSight from $5.50 to $6.30 and gave the company a "neutral" rating in a research note on Thursday. Jefferies Financial Group set a $6.50 price target on RxSight in a research note on Tuesday, July 7th. Wells Fargo & Company decreased their price target on RxSight from $11.00 to $9.00 and set an "equal weight" rating for the company in a report on Thursday, May 7th. Weiss Ratings lowered shares of RxSight from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, June 11th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of RxSight in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Reduce" and an average price target of $8.37. RxSight stock performance. Shares of RXST opened at $6.26 on Monday. RxSight has a fifty-two week low of $4.48 and a fifty-two week high of $13.22. The company has a market capitalization of $260.35 million, a price-to-earnings ratio of -5.54 and a beta of 1.13. The firm has a 50-day simple moving average of $5.31 and a 200-day simple moving average of $6.62. RxSight (NASDAQ:RXST - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. The firm had revenue of $33.74 million for the quarter, compared to analyst estimates of $32.55 million. RxSight had a negative return on equity of 17.35% and a negative net margin of 36.80%. Equities research analysts forecast that RxSight will post -1.31 EPS for the current year. Institutional investors weigh in on RxSight. A number of institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in shares of RxSight during the 2nd quarter worth approximately $28,000. Summit Securities Group LLC purchased a new stake in shares of RxSight in the first quarter valued at approximately $30,000. Larson Financial Group LLC boosted its stake in shares of RxSight by 110.5% in the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company's stock valued at $36,000 after buying an additional 2,089 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of RxSight by 440.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company's stock valued at $39,000 after buying an additional 3,063 shares in the last quarter. Finally, CWM LLC grew its holdings in RxSight by 211.1% during the fourth quarter. CWM LLC now owns 3,826 shares of the company's stock worth $40,000 after acquiring an additional 2,596 shares during the period. Hedge funds and other institutional investors own 78.78% of the company's stock. About RxSight. RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company's flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non-invasive post-operative adjustments. Using ultraviolet light, surgeons can fine-tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction. Discover more Dividend Screener Tool Stocks & Bonds Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider RxSight, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list. While RxSight currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Gunnamatta Media

Jul 17th, 2026

Plenty of interest in RxSight's Light Adjustable Lens at AUSCRS.

Plenty of interest in RxSight's Light Adjustable Lens at AUSCRS. Reading Time: 3 mins read RxSight believes Australian cataract surgeons are ready to embrace a technology that has already transformed refractive cataract surgery overseas, using this year's AUSCRS conference to showcase its Light Adjustable Lens (LAL) to the local market. More than 325,000 LALs have now been implanted globally, and with the system now available in Australia, RxSight general manager for Australia and New Zealand Amber Hext said the response from specialists at this week's AUSCRS conference on the Sunshine Coast had exceeded expectations. "There has been a lot of curiosity and a lot of questions about how the LAL can fit into people's practices," she said. "There has also been a healthy level of scepticism, which is great. It's given Insight News the opportunity to showcase the enormous amount of clinical data behind the technology, while also having Dr Baseer Khan on its stand to speak from experience. "Having someone who has performed more than 1,000 implants provides a peer-to-peer discussion that's beyond what we can do." Hext said many delegates had arrived already familiar with the technology from its international success and were eager to understand how they could begin offering it to Australian patients. The LAL is the world's only intraocular lens that can be adjusted after cataract surgery. Following implantation, surgeons use RxSight's Light Delivery Device (LDD) to apply targeted UV light treatments that reshape the lens, allowing postoperative refinement of refractive outcomes before the lens is permanently locked in. Rather than relying solely on preoperative calculations, the system enables surgeons to fine-tune vision after surgery, helping deliver a bespoke refractive result for each patient. Interest at AUSCRS centred on several key topics, including whether the lens delivers extended depth of focus (EDOF)-like performance despite not being classified as an EDOF IOL. "The other big question is who the lens is really for," Hext said. "Many surgeons initially think it's only suited to post-refractive surgery patients, but it's actually appropriate for a much broader cross-section of patients. That's been an important conversation." She said the ability to demonstrate the LDD in person and facilitate discussions with experienced users highlighted the value of exhibiting at conferences. "Marketing and publications all have an important place, but nothing replaces playing on the actual Light Delivery Device, talking to key opinion leaders and having those peer-to-peer conversations," she said. "Human connection always wins." With strong interest already generated, RxSight's next priority is supporting Australia's first wave of LAL adopters while it works towards broader market access. "We've already had surgeons saying, 'I want to get going. What are the next steps?'," Hext said. Early adopters will receive extensive clinical support, with RxSight building its Australian team while drawing on experienced international clinicians to assist with initial cases. "We have an incredible group of international experts who want to come over and support Australian surgeons," Hext said. "We'll be there for those first cases, and if surgeons want to explore the technology, we're ready to have that conversation."

RxSight

Engineer 1 - IOL Development

About the job